Related Experiment Video

Updated: Feb 22, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.8K

A new multifunctional hydroxytyrosol-fenofibrate with antidiabetic, antihyperlipidemic, antioxidant and

Yundong Xie1, Yanhong Xu1, Zizhang Chen1

  • 1College of Pharmacy, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi Province, 710061, People's Republic of China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|October 1, 2017
PubMed

Insights

This study developed a new compound, fenofibric acid-hydroxytyrosol (FF-HT), which effectively lowers lipids and blood sugar. FF-HT demonstrates significant antioxidant and anti-inflammatory effects, offering a promising approach for type 2 diabetes and atherosclerosis prevention.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Metabolic Diseases

Background:

  • Dyslipidemia, oxidative stress, and inflammation are key factors in type 2 diabetes mellitus (T2DM) and atherosclerosis.
  • Multifunctional therapeutic interventions are crucial for managing these complex conditions.

Purpose of the Study:

  • To evaluate the multifunctional effects of novel compounds combining fenofibric acid (FA) with tyrosol (T) or hydroxytyrosol (HT).
  • To assess the potential of these compounds in preventing T2DM and its complications.

Main Methods:

  • In vitro antioxidant capacity assays.
  • In vivo studies using hyperlipidemic mice induced by Triton WR 1339.
  • Evaluation in an experimental mouse model of T2DM.
  • Histological analysis of hepatic and pancreatic tissues.

Main Results:

  • FF-HT demonstrated superior antioxidant capacity compared to fenofibrate (FF).
  • FF-HT significantly reduced plasma triglyceride (TG), total cholesterol (TC), and malonaldehyde (MDA) levels in hyperlipidemic mice.
  • FF-HT exhibited antihyperglycemic, antihyperlipidemic, antioxidant, anti-inflammatory activities, and attenuated hepatotoxicity in a T2DM mouse model.
  • Histological examination revealed FF-HT suppressed hepatic lipid accumulation and ameliorated tissue damage.

Conclusions:

  • Optimized drug design can yield compound entities beneficial for preventing T2DM and its complications.
  • FF-HT represents a promising multifunctional agent for managing dyslipidemia, oxidative stress, and inflammation associated with T2DM and atherosclerosis.
Keywords:
Anti-diabetesAnti-inflammationAntihyperlipidemiaAntioxidantHydroxytyrosol-fenofibrate

More Related Videos

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

4.4K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
621
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
712
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
473
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
733